Alzheimer's Disease Analysis

Cobenfy meets endpoint in Bristol Myers Squibb’s Alzheimer’s psychosis trial

FDA · Alzheimer's disease · 6 min

Eisai's Leqembi Sales Forecast: A Turning Point?

FDA · Alzheimer's · 7 min

Biogen's Alzheimer's Data and Leadership Shake-up: Implications for Pharma BD

FDA · Alzheimer's disease · 10 min

Bristol Myers' Innovative Approach to Alzheimer's Beyond Amyloid

Alzheimer's disease · 3 min

FDA Breakthrough Therapy Designations: Impact on Neurological Disorder Investments 2026

FDA · neurological disorders · 11 min

Breakthrough Therapy Designations Drive Neurological Drug Innovation in US

FDA · neurological disorders · 4 min